)
)
)
Armatus Bio
Armatus Bio is a privately held, late preclinical-stage company utilizing vectorized RNAi in autosomal dominant neuromuscular diseases, with technology licensed from Nationwide Children’s Hospital in Columbus, Ohio. The company is advancing candidates for FSHD and CMT1A, both relatively common orphan indications with 40,000 and 70,000 affected patients in the US, respectively, and no FDA-approved medicines. Both of Armatus’ lead assets have completed preINDs and have been assigned ODD and RPD; the company is now preparing for IND-enabling studies, with the goal of delivering its first IND in 2026. Armatus is seeking Series A funding to advance the pipeline toward clinical proof of concept and is open to a range of investment and/or partnering opportunities.
Address
ColumbusOhio
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)